Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Press Releases
    REC   IT0003828271

RECORDATI

(REC)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/03 11:35:15 am
53.44 EUR   -0.52%
07:12aRECORDATI : EUSA Pharma Acquisition
PU
03:29aRecordati To Acquire EUSA Pharma In $847 Million Deal
MT
02:01aRecordati to buy EUSA Pharma for $847 million to boost rare disease offering
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société RECORDATI
07:12aRECORDATI : EUSA Pharma Acquisition
PU
01:52aRECORDATI : TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOC..
PU
12/01RECORDATI : Andrea recordati appointed chairman and robert koremans appointed chief execut..
PU
11/09Ultima presentazione del gruppo
PU
11/09Latest Company presentation
PU
10/29RECORDATI : Share buy-back program to service the stock option plans
PU
10/28RECORDATI : 2021 first nine months results approved. revenue +5.7%, ebitda +2.1% and net i..
PU
10/282021 First nine months results
PU
10/28RECORDATI : 2021 first nine months results approved. revenue +5.7%, ebitda +2.1% and net i..
PU
10/11RECORDATI : Resignation of a non-executive director
PU
10/11RECORDATI : 2022 corporate events' calendar
PU
07/30RECORDATI : Public disclosure
PU
07/29RECORDATI : First half of 2021 results approved, revenue +1.4%, ebitda -3.4%, net income +..
PU
07/16RECORDATI : Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Rec..
PU
07/14RECORDATI : Supports the forestami project
PU
07/09RECORDATI : Strengthening of the corporate governance
PU
05/25RECORDATI : The tenth edition of the arrigo recordati international prize for scientific r..
PU
05/06RECORDATI : 2021 Q1 Results2021 - 2023 Strategy and Outlook Update
PU
05/06RECORDATI : First quarter 2021 results and 2021-2023 three-year plan approved; 2023 revenu..
PU
05/05RECORDATI : Public disclosure (minutes of the ordinary general meeting of the shareholders..
PU
04/28RECORDATI : To present the first quarter 2021 results and the 2021-2023 strategy and outlo..
PU
04/22RECORDATI : Public disclosure (summary report of the votes - ordinary general meeting of t..
PU
04/12RECORDATI : The merger deed relating to the merger by absorption of rossini investimenti s..
PU
03/29RECORDATI : Public disclosure (documents relating to the ordinary general meeting of the s..
PU
03/25RECORDATI : Public disclosure (documents relating to the ordinary general meeting of the s..
PU
03/24RECORDATI : Ultima presentazione del gruppo
PU
03/24RECORDATI : Latest Company presentation
PU
03/24RECORDATI : Isturisa® (osilodrostat) approved in japan
PU
03/23RECORDATI : Recordati: positive results from the phase iii linc 4 study presented at the e..
PU
03/23RECORDATI RARE DISEASES : Positive Results From the Phase III LINC 4 Study Presented Today..
BU
03/19RECORDATI : Public disclosure (documents relating to the ordinary general meeting of the s..
PU
03/18RECORDATI : Board approves the 2020 accounts. sales € 1,448.9 million (-2.2%), ebitda € 56..
PU
02/23RECORDATI : Presentazione 2020 Preliminary FY Results
PU
02/22RECORDATI : Share buy-back program to service the stock option plans
PU
02/22RECORDATI : 2020 Preliminary FY results - 2021 Targets
PU
02/22RECORDATI : Preliminary 2020 results confirm continued growth of operating and net income...
PU
02/22RECORDATI : Preliminary 2020 results confirm continued growth of operating income and net ..
GL
01/26RECORDATI : CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hypera..
PU
2020RECORDATI : Public disclosure
PU
2020RECORDATI : Market authorization application for ars-1 (epinephrine nasal spray) accepted ..
PU
2020RECORDATI : Public disclosure
PU
2020RECORDATI : Merger by absorption of rossini investimenti s.p.a. and fimei s.p.a. intorecor..
PU
2020RECORDATI : Tax petition for the fruition of ace tax benefits deriving from the reverse me..
PU
2020RECORDATI : Call to an extraordinary general meeting of the shareholders 17.12.2020 (Rever..
PU
2020RECORDATI : Latest Company presentation
PU
2020RECORDATI : Ultima presentazione del gruppo
PU
2020RECORDATI : 2020 First nine months results
PU
2020RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebitda +7.1%, ..
PU
2020RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebitda +7.1%, ..
AQ
2020RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebitda +7.1%, ..
AQ
2020RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebitda +7.1%, ..
GL
2020RECORDATI : Publication of the information document relating to major transactions with re..
PU
2020RECORDATI : FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVE..
PU
2020RECORDATI : Reverse merger of Rossini Investimenti S.p.A. and Fimei S.p.A. with Recordati
PU
2020REVERSE MERGER OF ROSSINI INVESTIMEN : 2 ottobre 2020 - ore 8.30Dial in numbers:UK: +44 1 ..
PU
2020REVERSE MERGER OF ROSSINI INVESTIMEN : 2020, October 2 - 8.30am CETDial in numbers:UK: +44..
PU
2020RECORDATI : Recordati: merger by absorption of fimei s.p.a. and rossini investimenti s.p.a..
PU
2020RECORDATI : Merger by absorption of fimei s.p.a. and rossini investimenti s.p.a. into reco..
AQ
2020RECORDATI : Merger by absorption of fimei s.p.a. and rossini investimenti s.p.a. into reco..
AQ
2020RECORDATI : Merger by absorption of fimei s.p.a. and rossini investimenti s.p.a. into reco..
GL
2020RECORDATI : Licenses an innovative epinephrine nasal spray in development for anaphylaxis ..
AQ
2020Recordati licenses an innovative epinephrine nasal spray in development for anaphylaxis..
GL
2020RECORDATI : Ultima presentazione del gruppo
PU
2020RECORDATI : Latest Company presentation
PU
2020RECORDATI : Adempimenti informativi verso il pubblico
PU
2020RECORDATI : Public disclosure compliance
PU
2020RECORDATI : EY Report on the Interim Condensed Consolidated Financial Statements as at and..
PU
2020RECORDATI : First half 2020
PU
2020Recordati announces positive first half 2020 results. revenues +2.3%, ebitda +11.4%, ad..
GL
2020RECORDATI : Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) f..
BU
2020RECORDATI : Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Ge..
BU
2020RECORDATI RARE DISEASES : Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primar..
BU
2020RECORDATI : Isturisa® (osilodrostat) phase iii linc-4 trial meets its primary endpoint in ..
AQ
2020RECORDATI RARE DISEASES : Announces First European Launch of Isturisa® (osilodrostat)
BU
2020RECORDATI : May 2020 - Company presentation
PU
1  2  3  4Next
Upcoming event on RECORDATI